Anthrax Vaccine Market 2025–2029: Strategic Opportunities and Growth Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the anthrax vaccine market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Anthrax Vaccine Market Now And By 2029?

The anthrax vaccine market size has experienced consistent expansion over recent years. It is anticipated to increase from $11.27 billion in 2024 to $11.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.4%. The historic development of this market is linked to issues such as biological warfare concerns, requirements from the military, instances of anthrax outbreaks, public health readiness, and biodefense initiatives.

The anthrax vaccine market is anticipated to experience consistent expansion over the coming years. Its size is expected to reach $14 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.4%. This expansion during the forecast period is driven by global security challenges, the emergence of new threats, government procurement initiatives, and enhanced pandemic preparedness. Significant trends expected during this period encompass technological advancements, improved accessibility in developing countries, a focus on next-generation vaccines, increased government stockpiling, and collaborative research efforts.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

Which Long-Term Drivers Are Expected To Sustain The Anthrax Vaccine Market?

The increasing occurrence of infectious diseases is anticipated to boost the expansion of the anthrax vaccine market in the future. These diseases are defined as ailments resulting from pathogenic microorganisms like bacteria, viruses, parasites, or fungi, capable of transmitting directly or indirectly between individuals, frequently causing symptoms that vary from mild to severe, and occasionally fatal, contingent on the specific pathogen and the host’s immune reaction. Their widespread presence stems from global demographic shifts, urbanization, alterations in environmental conditions and land utilization, and evolving human behaviors. While primarily used for protection against anthrax, the anthrax vaccine’s broader applicability in preventing other infectious diseases is under investigation, focusing on its immunogenic traits and adaptability. For example, data from February 2023 by the US-based nonprofit Council on Foreign Relations indicated that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of established infectious diseases originated from zoonoses. Globally, zoonotic diseases are responsible for 2.7 million human deaths and 2.5 billion disease incidents annually. Consequently, the increasing prevalence of these diseases is fueling the expansion of the anthrax vaccine market.

How Is The Anthrax Vaccine Market Classified By Different Segments?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

What Current And Upcoming Trends Are Shaping The Anthrax Vaccine Market?

Leading companies in the anthrax vaccine market are concentrating on creating innovative products and securing FDA approvals for their vaccines to guarantee safety, effectiveness, and availability for those at risk of anthrax exposure. Gaining FDA approval confirms that the vaccine has undergone rigorous testing in clinical trials and is confirmed safe for public consumption. This helps safeguard individuals from potential adverse reactions. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received clearance for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously identified as AV7909, from the U.S. Food and Drug Administration (FDA). This approval was based on findings from a Phase 2 trial assessing Cyfendus’s non-interference with antibacterial drugs and Phase 3 clinical research comparing the vaccine’s immunogenicity and safety to BioThrax, the predecessor anthrax vaccine. Furthermore, the creation of safer and more potent adjuvants is crucial for resolving reactogenicity issues and boosting the overall efficiency of anthrax vaccines.

Who Are The Primary Market Leaders In The Anthrax Vaccine Market?

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Anthrax Vaccine Market?

North America was the largest region in the anthrax vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

Browse Through More Reports Similar to the Global Anthrax Vaccine Market 2025, By The Business Research Company

Influenza Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Inactivated Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Human Papillomavirus Hpv Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/human-papillomavirus-hpv-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795